VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for VANFLYTA, approved for newly diagnosed FLT3-ITD positive acute myeloid leukemia in combination and maintenance settings.
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for REZLIDHIA, approved for adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.